(NASDAQ: RVPH) Reviva Pharmaceuticals Holdings's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 5.42%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.25%.
Reviva Pharmaceuticals Holdings's earnings in 2025 is -$27,111,725.On average, 3 Wall Street analysts forecast RVPH's earnings for 2025 to be -$40,577,756, with the lowest RVPH earnings forecast at -$55,762,963, and the highest RVPH earnings forecast at -$29,921,590. On average, 2 Wall Street analysts forecast RVPH's earnings for 2026 to be -$29,581,572, with the lowest RVPH earnings forecast at -$36,721,951, and the highest RVPH earnings forecast at -$22,441,192.
In 2027, RVPH is forecast to generate -$10,880,578 in earnings, with the lowest earnings forecast at -$10,880,578 and the highest earnings forecast at -$10,880,578.